Asset Details
Do you wish to reserve the book?
Thrombocytopenia Induced by Imatinib Mesylate(Glivec) in Patients with Chronic Myelogenous Leukemia : Is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Thrombocytopenia Induced by Imatinib Mesylate(Glivec) in Patients with Chronic Myelogenous Leukemia : Is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
Do you wish to request the book?
Thrombocytopenia Induced by Imatinib Mesylate(Glivec) in Patients with Chronic Myelogenous Leukemia : Is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Thrombocytopenia Induced by Imatinib Mesylate(Glivec) in Patients with Chronic Myelogenous Leukemia : Is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
2003
Publisher
Springer Nature B.V
Subject
/ Aged
/ Female
/ Humans
/ Japan
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Male
/ Piperazines - administration & dosage
/ Piperazines - adverse effects
/ Pyrimidines - administration & dosage
